Moderator: Thomas Dörner (Germany)
	Remission and low disease activity: the new targets for treatment	George Bertsias (Greece)
	Belimumab helps lupus patients to achieve lupus targets	Andrea Doria (Italy)
	Can we withdraw low-dose prednisone in remitted patients?	Zahir Amoura (France)
	Can we withdraw immunosuppressants in remitted patients?	Margherita Zen (Italy)
	Panel Discussion and Q&A	All